- (PLX AI) – Lundbeck's Vyepti recommended for approval in the EU by CHMP for the preventive treatment of migraine in adults.
- • Subject to final approval by the European Commission, Vyepti (eptinezumab) will be the first intravenous (IV) treatment approved for migraine prevention in Europe
- • A final decision regarding the approval of Vyepti is expected from the European Commission in the coming months